Céline Robert-Tissot

Princess Margaret Cancer Centre University Health Network

关注

立即认领

关注

立即认领

基本信息

浏览量：6

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 31 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

时间

引用量

主题

期刊级别

合作者

合作机构

Supplementary Figure 1 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

Justin F. Gainor,Manish R. Patel,Jeffrey S. Weber,Martin Gutierrez,Julie E. Bauman,Jeffrey M. Clarke,Ricklie Julian,Aaron J. Scott,Jessica L. Geiger,Kedar Kirtane,Celine Robert-Tissot,Brandon Coder,Moomal Tasneem, Jing Sun, Wei Zheng,Lauren Gerbereux,Andressa Laino,Filippos Porichis,Jack Russella Pollard,Peijie Hou,Vasudha Sehgal, Xing Chen,Manju Morrissey,Hikmat N. Daghestani,Igor Feldman,Lakshmi Srinivasan,Joshua P. Frederick,Michelle Brown,Praveen Aanur,Robert Meehan,Howard A. Burris

crossref（2024）

引用0浏览0引用

Supplementary Figure 8 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

crossref（2024）

引用0浏览0引用

T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

CANCER DISCOVERYno. 11 (2024): 2209-2223

引用0浏览0WOS引用

Supplementary Figure 2 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

crossref（2024）

引用0浏览0引用

Supplementary Table 2 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

crossref（2024）

引用0浏览0引用

Supplementary Figure 3 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

crossref（2024）

引用0浏览0引用

Individualised Neoantigen Therapy Mrna-4157 (V940) Plus Pembrolizumab Versus Pembrolizumab Monotherapy in Resected Melanoma (KEYNOTE-942): a Randomised, Phase 2b Study

Jeffrey S. Weber,Matteo S. Carlino,Adnan Khattak,Tarek Meniawy,George Ansstas,Matthew H. Taylor,Kevin B. Kim,Meredith McKean,Georgina Long,Ryan J. Sullivan,Mark Faries,Thuy T. Tran,C. Lance Cowey,Andrew Pecora,Montaser Shaheen,Jennifer Segar,Theresa Medina,Victoria Atkinson,Geoffrey T. Gibney,Jason J. Luke,Sajeve Thomas,Elizabeth Buchbinder,Jane A. Healy,Mo Huang,Manju Morrissey,Igor Feldman,Vasudha Sehgal,Celine Robert-Tissot,Peijie Hou, Lili Zhu,Michelle Brown,Praveen Aanur,Robert S. Meehan,Tal Zaks

LANCETno. 10427 (2024): 632-644

引用76浏览0WOS引用

Supplementary Figure 6 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

crossref（2024）

引用0浏览0引用

Supplementary Table 4 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

crossref（2024）

引用0浏览0引用

Supplementary Table 3 from T-cell Responses to Individualized Neoantigen Therapy Mrna-4157 (V940) Alone or in Combination with Pembrolizumab in the Phase 1 KEYNOTE-603 Study

crossref（2024）

引用0浏览0引用

加载更多

作者统计

#Papers: 31

#Citation: 541

H-Index: 11

G-Index: 16

Sociability: 5

Diversity: 2

Activity: 22

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn